The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR inhibitors) in patients with advanced CLL unresponsive to standard therapies and to determine the appropriate dosing level and regimen for later-stage clinical trials (NCT01353625). The medication will be taken orally. As a result of consequent translational efforts, we are now able to recruit genetically-stratified CLL patients into this trial. The molecular rationale for this novel treatment regimen was devised by scientists of our clinical research unit-286 (Riabinska et al., 2013). For any questions regarding this trial, please contact either Christian Reinhardt or Barbara Eichhhorst, who is serving as our leading clinical investigator.